ArticleMedicine2026
Prognostic model based on stem cells and oxidative stress related genes for ovarian cancer.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer (OC) is a common gynecological condition. Cancer stem cells (CSCs) are tumor cells with the potential to differentiate and self-renew. The aim of this study was to identify genes relevant to stem cells and oxidative stress (OS) in OC and to construct corresponding prognostic models. OS-related genes were obtained from GenBank. The mRNAsi-OS differentially expressed genes (DEGs) were filtered by overlapping OS-related genes, DEGs associated with mRNAsi, and DEGs in OC. Then, the Absolute Shrinkage and Selection Operator (LASSO) algorithm and univariate Cox regression were adopted to construct an OS-mRNAsi-related prognostic model. Subsequently, we validated the predictive value of the model using both the training and validation sets. The differences in immune infiltration and immunotherapy between the OS-CSC-related high- and low-risk subgroups were further explored. Finally, we analyzed the drug sensitivity between the 2 subgroups. A total of 5 prognostic genes (PLK2, CACNA1C, PENK, NR0B1, and HNF4A) related to CSC and OS were screened. The area under the curve (AUC) value of the prognostic model in predicting the 3-, 5-, and 7-year survival rate of patients with OC was >0.6, which revealed that the efficiency of the prognostic model was acceptable. The results of CIBERSORT demonstrated noticeable differences in the tumor microenvironment between the OS-CSC-related high- and low-risk subgroups. In addition, the risk score obtained based on OS and mRNAsi can be used to estimate the effectiveness of immunotherapy in patients with OC. Finally, the sensitivity of 5 common drugs (docetaxel, cisplatin, doxorubicin, mitomycin C, and paclitaxel) was evaluated using an OS-CSC-related prognostic model. In conclusion, an OS-CSC-related prognostic model based on 5 genes (PLK2, CACNA1C, PENK, NR0B1, and HNF4A) was constructed using bioinformatics analysis, which may provide new insights into the treatment and evaluation of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.